title: Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer.
abstract: Psoriasis is a chronic relapsing immunoinflammatory dermatosis that is commonly associated with systemic comorbidities. The pathogenic importance of interleukin (IL)-12 and IL-23 is beyond doubt, as well as the involvement of T helper cells (Th)1 and Th17 cells. There is upregulation of the p40 subunit shared by IL-12 and IL-23 and of the IL-23 p19 subunit, but not an increased expression of the IL-12 p35 subunit. This indicates that IL-23 appears more involved than IL-12 in the pathogenesis of psoriatic plaques. Ustekinumab is a fully human monoclonal antibody of the immunoglobulin (Ig) G1 class targeting the p40 subunit common to both IL-12 and IL-23, thus inhibiting both IL-12 and IL-23 receptor-mediated signalling. Ustekinumab is part of the recent biologic therapies active in psoriasis, autoimmune arthritides, and inflammatory bowel diseases.
authors: Department of Dermatopathology, University Hospital of Liège, 4000 Liège, Belgium.
authors: Pascale
authors: P
authors: Quatresooz
authors: Trinh
authors: T
authors: Hermanns-Lê
authors: Gérald E
authors: GE
authors: Piérard
authors: Philippe
authors: P
authors: Humbert
authors: Philippe
authors: P
authors: Delvenne
authors: Claudine
authors: C
authors: Piérard-Franchimont
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D018664:Interleukin-12 / Q000276:immunology; D053759:Interleukin-23 / Q000276:immunology*; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D058504:Th17 Cells / Q000276:immunology*; D000069549:Ustekinumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053759:Interleukin-23; D018664:Interleukin-12; D000069549:Ustekinumab